1. Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

2. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Table 1. Key Demographic and Baseline Characteristics for Patients by EGFR Mutation Status

3. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Table 2. Baseline EGFR Mutation Status.

4. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Table 3. Best Overall Response in the Overall Population, EGFR Mutation-Positive Patients, EGFR Mutation-Negative Patients, and Patients with Unknown EGFR Mutation Status (ITT Population).

5. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Table 3. No caption available.

6. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Table 3. No caption available.

7. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Figure 1.

8. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 8 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Figure 2.

9. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 9 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, 2009. Supplemental Figure 3